Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06537999 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
A Phase 2 study of Multifocal Motor Neuropathy, sponsored by Dianthus Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT06537999: Recruiting Phase 2 study of Multifocal Motor Neuropathy, sponsored by Dianthus Therapeutics.
NCT06537999 is a Phase 2 study of Multifocal Motor Neuropathy that is actively recruiting participants, run by Dianthus Therapeutics. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06537999, a Phase 2 study of Multifocal Motor Neuropathy, is actively recruiting participants, sponsored by Dianthus Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).
Primary Outcome
Incidence of treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (SAEs)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DNTH103
Study Locations (20)
Other
- Clinical Study Site - Aarhus
- Clinical Study Site - Copenhagen
- Clinical Study Site - Marseille
- Clinical Study Site - Paris
- Clinical Study Site - Rome
- Clinical Study Site - Amsterdam
- Clinical Study Site - Utrecht
- Clinical Study Site - Skopje
- Clinical Study Site - Bydgoszcz
- Clinical Study Site - Katowice
Florida
- Clinical Study Site - Bradenton
- Clinical Study Site - Tampa
Ohio
- Clinical Study Site - Cincinnati
- Clinical Study Site - Columbus
Arizona
- Clinical Study Site - Scottsdale
California
- Clinical Study Site - Los Angeles
Hawaii
- Clinical Study Site - Honolulu
Kansas
- Clinical Study Site - Kansas City
North Carolina
- Clinical Study Site - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
What NCT06537999 shows while recruiting
NCT06537999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Multifocal Motor Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06537999 names 20 study sites across 9 states, led by Other, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06537999 about?
NCT06537999 is a clinical study titled "A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy". The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).
What is the current status of trial NCT06537999?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-09-17. Estimated completion is 2028-03-31.
What conditions does trial NCT06537999 study?
This clinical trial studies the following conditions: Multifocal Motor Neuropathy.
What interventions are being tested in trial NCT06537999?
The interventions under investigation include: Placebo (DRUG), DNTH103 (DRUG).
Who is sponsoring clinical trial NCT06537999?
This trial is sponsored by Dianthus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06537999 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Hawaii, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multifocal Motor Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06537999's enrollment target sits among peer trials
36 1496th of 2000 higher than 478 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI